Synthesis and evaluation of the anti-inflammatory activity of N-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-4-oxothiazolidin-3-yl]-nicotinamide

Rajiv Kalia, Chamallamudi Mallikarjuna Rao, Nampurath Gopalan Kutty

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A new molecule incorporating nicotinoyl moiety, thiazolidin-4-one ring and 3,5-di-tert-butyl-4-hydroxyphenyl group (a potent antioxidant moiety) was synthesized and evaluated for anti-inflammatory activity in acute as well as chronic phase models of inflammation. The compound exhibited significant anti-inflammatory activity in three experimental models of inflammation, comparable to the positive control drug, ibuprofen (CAS 15687-27-1). It is suggested that besides the hypolipidemic and antioxidant potential of the molecule, its anti-inflammatory action could possibly act as an additional mechanism of its hypothesized anti-atherosclerotic activity.

Original languageEnglish
Pages (from-to)616-622
Number of pages7
JournalArzneimittel-Forschung/Drug Research
Volume57
Issue number9
Publication statusPublished - 2007

Fingerprint

Anti-Inflammatory Agents
Antioxidants
Inflammation
Ibuprofen
Drug and Narcotic Control
Theoretical Models
N-(2-(3,5-di-tert-butyl-4-hydroxyphenyl)-4-oxo-thiazolidin-3-yl)-nicotinamide
3,5-di-tert-butyl-4-hydroxyphenyl

All Science Journal Classification (ASJC) codes

  • Drug Discovery

Cite this

@article{c0d6557bd8334aa29d04d6e3628e5a87,
title = "Synthesis and evaluation of the anti-inflammatory activity of N-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-4-oxothiazolidin-3-yl]-nicotinamide",
abstract = "A new molecule incorporating nicotinoyl moiety, thiazolidin-4-one ring and 3,5-di-tert-butyl-4-hydroxyphenyl group (a potent antioxidant moiety) was synthesized and evaluated for anti-inflammatory activity in acute as well as chronic phase models of inflammation. The compound exhibited significant anti-inflammatory activity in three experimental models of inflammation, comparable to the positive control drug, ibuprofen (CAS 15687-27-1). It is suggested that besides the hypolipidemic and antioxidant potential of the molecule, its anti-inflammatory action could possibly act as an additional mechanism of its hypothesized anti-atherosclerotic activity.",
author = "Rajiv Kalia and Rao, {Chamallamudi Mallikarjuna} and {Gopalan Kutty}, Nampurath",
year = "2007",
language = "English",
volume = "57",
pages = "616--622",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "9",

}

TY - JOUR

T1 - Synthesis and evaluation of the anti-inflammatory activity of N-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-4-oxothiazolidin-3-yl]-nicotinamide

AU - Kalia, Rajiv

AU - Rao, Chamallamudi Mallikarjuna

AU - Gopalan Kutty, Nampurath

PY - 2007

Y1 - 2007

N2 - A new molecule incorporating nicotinoyl moiety, thiazolidin-4-one ring and 3,5-di-tert-butyl-4-hydroxyphenyl group (a potent antioxidant moiety) was synthesized and evaluated for anti-inflammatory activity in acute as well as chronic phase models of inflammation. The compound exhibited significant anti-inflammatory activity in three experimental models of inflammation, comparable to the positive control drug, ibuprofen (CAS 15687-27-1). It is suggested that besides the hypolipidemic and antioxidant potential of the molecule, its anti-inflammatory action could possibly act as an additional mechanism of its hypothesized anti-atherosclerotic activity.

AB - A new molecule incorporating nicotinoyl moiety, thiazolidin-4-one ring and 3,5-di-tert-butyl-4-hydroxyphenyl group (a potent antioxidant moiety) was synthesized and evaluated for anti-inflammatory activity in acute as well as chronic phase models of inflammation. The compound exhibited significant anti-inflammatory activity in three experimental models of inflammation, comparable to the positive control drug, ibuprofen (CAS 15687-27-1). It is suggested that besides the hypolipidemic and antioxidant potential of the molecule, its anti-inflammatory action could possibly act as an additional mechanism of its hypothesized anti-atherosclerotic activity.

UR - http://www.scopus.com/inward/record.url?scp=35048818014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35048818014&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 616

EP - 622

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 9

ER -